Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor
CONCLUSION: The presence of sarcopenia or myosteatosis is a reliable predictor of the clinical outcomes of patients with GC who are undergoing treatment with an ICI.PMID:38516238 | PMC:PMC10950641 | DOI:10.3748/wjg.v30.i8.863
Source: World Journal of Gastroenterology - Category: Gastroenterology Authors: Gui-Ming Deng Hai-Bin Song Zhong-Ze Du Ying-Wei Xue Hong-Jiang Song Yuan-Zhou Li Source Type: research
More News: Cancer | Cancer & Oncology | CT Scan | Gastric (Stomach) Cancer | Gastroenterology | Immunotherapy | Nutrition | Study